[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354584-105":59,"doc-detail-354584-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","evidence-for-the-prognostic-value-of-tp53-mutations-in-circulating-tumor-dna-across-solid-malignancies-a-systematic-review-and-meta-analysis","Evidence for the prognostic value of TP53 mutations in circulating tumor DNA across solid malignancies - a systematic review and meta-analysis","","This systematic review and meta-analysis evaluates clinical utility of TP53 mutations in circulating tumor DNA (ctDNA) as a prognostic biomarker across solid malignancies. PubMed, Embase, Cochrane, and Web of Science were searched through May 2025 for studies linking TP53 mutations in ctDNA/cfDNA to survival outcomes. Twenty-one studies were analyzed using STATA, fixed and random effects, hazard ratios with 95% CIs, and quality assessment by NOS. Mutated patients showed poorer PFS, shorter OS, and reduced DFS, while RFS was not significantly different.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/evidence-for-the-prognostic-value-of-tp53-mutations-in-circulating-tumor-dna-across-solid-malignancies-a-systematic-review-and-meta-analysis/354584/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/evidence-for-the-prognostic-value-of-tp53-mutations-in-circulating-tumor-dna-across-solid-malignancies-a-systematic-review-and-meta-analysis/354584.png","ImageObject",300,407,{"name":92,"@type":93},"nayy☆","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the purpose of this meta-analysis?","Question",{"text":113,"@type":114},"To provide evidence for the clinical utility of TP53 mutations in circulating tumor DNA (ctDNA) as a prognostic biomarker across solid malignancies.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were eligible studies selected and analyzed?",{"text":118,"@type":114},"Databases including PubMed, Embase, Cochrane, and Web of Science were searched up to May 2025. Quality was assessed with the Newcastle-Ottawa Scale, and meta-analysis was performed in STATA 16.0 using hazard ratios with fixed- and random-effects models.",{"name":120,"@type":111,"acceptedAnswer":121},"What prognostic effects were found for TP53-mutated ctDNA patients?",{"text":122,"@type":114},"TP53-mutated patients had worse progression-free survival (PFS), shorter overall survival (OS), and reduced disease-free survival (DFS). RFS did not show a statistically significant difference.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},354584,1790190871,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Jinyan et al. BMC Cancer (2026) 26:977 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-16265-y](https://doi.org/10.1186/s12885-026-16265-y)  \nSYSTEMATIC REVIEW Open Access  \nEvidence for the prognostic value ofTP53 mutations in circulating tumor DNA across solid malignancies: a systematic review and meta-analysis  \nLan Jinyan1, Liang Yibin1*, Qin Jiangkui1, Huang Shanbo2, Glenn Deng3, Changsheng Sun4, He Yongyu1, Huang Gang2 andYiTingzhuang1*  \nAbstract  \nBackground The purpose of this meta-analysis study is to provide evidence for the clinical utility ofTP53 mutations in circulating tumor DNA (ctDNA) as a prognostic biomarker.  \nMethods We searched the PubMed, Embase, Cochrane, and Web of Science databases (last update May 2025) for studies on TP53 mutations in ctDNA or cfDNA as prognosis overall survival and in solid tumors. A total of 21 studies that met the criteria were utilized and data was collected regarding the authors, year of publication, study design, site of the study, number of patients, detection, mutation sample size and outcome measures were collected. The Newcastle-Ottawa Scale (NOS) was used to evaluate the quality of the study, and meta-analysis was done by using STATA 16.0. Effect sizes were in the form of hazard ratios (HR) that had 95% confidence intervals (CI) . The models used were fixed-effects and random-effects based on heterogeneity. Funnel plots, and Egger’s test was used to measure publication bias, and sensitivity analysis conducted through a leave-one-out method.  \nResults A total of 21 studies (2,685 TP53-mutated patients, one unreported) showed: Mutated patients had worse progression-free survival (PFS) (HR=2 . 10, p=0 . 000; 12 studies, heterogeneity resolved after excluding Yoshida 2023), shorter OS (HR=1 . 74, p=0 . 014; 9 studies), and reduced DFS (HR=1 . 73, p=0 . 007; 3 studies), but RFS (2 items) showed no statistically significant differences. Subgroup analyses revealed: Prospective studies showed stronger PFS (HR=2 .14 vs retrospective 1. 90) with Japanese subgroup HR=4 . 90; Lung/liver cancers had higher HRs than breast. Prospective OS HR=2.25 (lung 3.14, endometrial 0.75). Retrospective DFS HR=1.89 vs Japanese breast RFS HR=4.00. Heterogeneity originated from study design, region, and cancer type variations, with no significant publication bias (Egger's test p>0 . 05) .  \nConclusion Current evidence suggests that TP53 mutations detected in ctDNA are significantly associated with poor prognosis in various solid tumors, particularly lung cancer. The association is robust for PFS and OS, though  \n*Correspondence: Liang Yibin [1693535705@qq.com](1693535705@qq.com)[ ](1693535705@qq.com)Yi Tingzhuang [ytz20070101@163.com](ytz20070101@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nJinyan et al. BMC Cancer (2026) 26:977 Page 2 o","cbCaijKzRISJNbpa","https://ap.wps.com/l/cbCaijKzRISJNbpa","pdf",1319618,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n## Strengths and limitations","[{\"question\":\"What was the purpose of this meta-analysis?\",\"answer\":\"To provide evidence for the clinical utility of TP53 mutations in circulating tumor DNA (ctDNA) as a prognostic biomarker across solid malignancies.\"},{\"question\":\"How were eligible studies selected and analyzed?\",\"answer\":\"Databases including PubMed, Embase, Cochrane, and Web of Science were searched up to May 2025. Quality was assessed with the Newcastle-Ottawa Scale, and meta-analysis was performed in STATA 16.0 using hazard ratios with fixed- and random-effects models.\"},{\"question\":\"What prognostic effects were found for TP53-mutated ctDNA patients?\",\"answer\":\"TP53-mutated patients had worse progression-free survival (PFS), shorter overall survival (OS), and reduced disease-free survival (DFS). RFS did not show a statistically significant difference.\"}]","Evidence for the prognostic value of TP53 mutations in circulating tumor DNA across solid malignancies - a systematic review and meta-analysis | PDF",1790112326,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/63eaada23a33e1f532366c16ffd1bca7.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/595b0dc16abeacbd9874f08fb8ea122f.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/535a2a062307621c97a4a60a0593a68f.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0c9892f221d57fd300a0c26eda26f7d7.webp",980,1306]